X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
reducing agents (36) 36
humans (34) 34
index medicus (31) 31
acid-reducing agents (29) 29
drug interactions (26) 26
pharmacology & pharmacy (26) 26
male (20) 20
female (18) 18
adult (16) 16
pharmacokinetics (16) 16
hydrogen-ion concentration (12) 12
middle aged (12) 12
hiv infections - drug therapy (11) 11
omeprazole (11) 11
acids (10) 10
proton pump inhibitors (10) 10
antacids (9) 9
atazanavir (9) 9
protease inhibitors (9) 9
solubility (9) 9
absorption (8) 8
animals (8) 8
chemistry, multidisciplinary (8) 8
drug-drug interaction (8) 8
nanoparticles (8) 8
analysis (7) 7
ascorbic acid (7) 7
gold (7) 7
healthy-volunteers (7) 7
hiv (7) 7
infectious diseases (7) 7
ph (7) 7
pharmacology/toxicology (7) 7
reducing agent (7) 7
silver (7) 7
area under curve (6) 6
atazanavir sulfate (6) 6
drug-drug interactions (6) 6
hiv protease inhibitors - pharmacokinetics (6) 6
nanoscience & nanotechnology (6) 6
organic chemistry (6) 6
proton pump inhibitor (6) 6
ritonavir (6) 6
acetic acid (5) 5
acid-reducing agent (5) 5
administration, oral (5) 5
adolescent (5) 5
ascorbic-acid reduction (5) 5
bioavailability (5) 5
biochemistry, general (5) 5
biological availability (5) 5
biomedicine (5) 5
gastric ph (5) 5
hiv protease inhibitors - therapeutic use (5) 5
oxidation (5) 5
pharmacology (5) 5
pharmacy (5) 5
proton-pump inhibitors (5) 5
ranitidine (5) 5
acid reduction (4) 4
adsorption (4) 4
antacids - therapeutic use (4) 4
antiviral agents (4) 4
catalysis (4) 4
catalysts (4) 4
chemical synthesis (4) 4
chemistry, organic (4) 4
chemistry, physical (4) 4
concretes (4) 4
cross-over studies (4) 4
drug (4) 4
drug administration schedule (4) 4
drug therapy (4) 4
drugs (4) 4
fluorescent indicators (4) 4
hiv infections - virology (4) 4
hiv protease inhibitors - adverse effects (4) 4
hiv-infected patients (4) 4
human-immunodeficiency-virus (4) 4
immunology (4) 4
materials science, multidisciplinary (4) 4
medicine, research & experimental (4) 4
omeprazole - administration & dosage (4) 4
proton pump inhibitors - adverse effects (4) 4
proton pump inhibitors - therapeutic use (4) 4
pyridines - pharmacokinetics (4) 4
reagents (4) 4
reduction (4) 4
research (4) 4
retrospective studies (4) 4
risk factors (4) 4
sulfonamides - pharmacokinetics (4) 4
therapy (4) 4
acid (3) 3
acid‐reducing agent (3) 3
acrylic acid (3) 3
active antiretroviral therapy (3) 3
agents (3) 3
aids/hiv (3) 3
antacids - administration & dosage (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Clinical Pharmacology, ISSN 0091-2700, 08/2019, Volume 59, Issue 8, pp. 1093 - 1098
Journal Article
European Journal of Cancer, ISSN 0959-8049, 07/2019, Volume 116, pp. 45 - 55
We conducted a retrospective analysis to evaluate the impact of concomitant acid-reducing agents (ARAs) and vemurafenib dose on the efficacy of vemurafenib in... 
Vemurafenib | Cobimetinib | Acid-reducing agents | Drug interactions | Melanoma | Dosing | Effectiveness | Acids | Reducing agents | Metastasis | Mutation | Survival | Steady state | Subgroups | Metastases
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 07/2016, Volume 5, Issue 4, pp. 269 - 277
Paritaprevir (administered with low‐dose ritonavir), ombitasvir, and dasabuvir are direct‐acting antiviral agents administered as combination regimens for the... 
hepatitis C virus | omeprazole | drug–drug interaction | CYP2C19 | acid‐reducing agent | Omeprazole | Acid-reducing agent | Drug-drug interaction | Hepatitis C virus | acid-reducing agent | GASTRIC-ACID-SECRETION | ABT-450/R-OMBITASVIR | CHRONIC HEPATITIS-C | RIBAVIRIN | METABOLISM | CYTOCHROME-P450 ENZYMES | TREATMENT-EXPERIENCED PATIENTS | PROTON PUMP INHIBITOR | PHARMACOLOGY & PHARMACY | drug-drug interaction | RITONAVIR | Antiviral Agents - pharmacokinetics | Area Under Curve | Humans | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Carbamates - pharmacokinetics | Macrocyclic Compounds - pharmacology | Anti-Ulcer Agents - pharmacokinetics | Uracil - pharmacology | Drug Interactions | Uracil - administration & dosage | Cytochrome P-450 CYP2C19 - drug effects | Adult | Anti-Ulcer Agents - pharmacology | Female | Omeprazole - pharmacology | Ritonavir - pharmacology | Drug Therapy, Combination | Carbamates - pharmacology | Antiviral Agents - pharmacology | Ritonavir - administration & dosage | Omeprazole - administration & dosage | Macrocyclic Compounds - pharmacokinetics | Omeprazole - pharmacokinetics | Sulfonamides - pharmacology | Antiviral Agents - administration & dosage | Sulfonamides - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Ritonavir - pharmacokinetics | Anilides - administration & dosage | Anilides - pharmacology | Cytochrome P-450 CYP2C19 - metabolism | Macrocyclic Compounds - administration & dosage | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Uracil - analogs & derivatives
Journal Article
Jingxi Huagong = Fine Chemicals, ISSN 1003-5214, 01/2018, Volume 35, Issue 8, p. 1421
The sulfonic acid group/carboxy cellulose ester (CLCSC) was synthesized by a one-pot method using Xinjiang cotton short velvet as raw material, sulfamic acid... 
Anhydrides | Viscosity | Cellulose esters | Nuclear magnetic resonance--NMR | Cellulose | Compression tests | Reducing agents | Cotton | Sulfonic acid | Esterification | Molecular weight | Bleeding | Substitutes | Concretes | pH
Journal Article
EUROPEAN JOURNAL OF CANCER, ISSN 0959-8049, 07/2019, Volume 116, pp. 45 - 55
Background: We conducted a retrospective analysis to evaluate the impact of concomitant acid-reducing agents (ARAs) and vemurafenib dose on the efficacy of... 
DRUG | Vemurafenib | ESOMEPRAZOLE | Cobimetinib | PHARMACOKINETICS | EFFICACY | ONCOLOGY | Acid-reducing agents | Drug interactions | Melanoma | BIOAVAILABILITY
Journal Article
Journal of Clinical Pharmacology, ISSN 0091-2700, 05/2008, Volume 48, Issue 5, pp. 553 - 562
A total of 71 HIV-negative healthy adults were randomized to 1 of 6 regimens to receive lopinavir/ritonavir tablets 400/100 mg twice daily (bid) or 800/200 mg... 
Atazanavir | Pharmacokinetics | Acid-reducing agents | Ritonavir | Lopinavir | acid-reducing agents | lopinavir | EFFICACY | atazanavir | ritonavir | pharmacokinetics | VALIDATION | PHARMACOLOGY & PHARMACY | CLINICAL PHARMACOKINETICS | PROTEASE INHIBITORS | Area Under Curve | Ranitidine - pharmacokinetics | Humans | Middle Aged | Pyridines - pharmacokinetics | Biological Availability | Male | Anti-HIV Agents - administration & dosage | Anti-Ulcer Agents - pharmacokinetics | Dose-Response Relationship, Drug | Histamine H2 Antagonists - administration & dosage | Drug Interactions | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Adult | Female | Ranitidine - adverse effects | Anti-HIV Agents - blood | HIV Protease Inhibitors - blood | Pyridines - administration & dosage | Oligopeptides - blood | Ritonavir - administration & dosage | Ritonavir - blood | Oligopeptides - pharmacokinetics | Omeprazole - administration & dosage | Anti-Ulcer Agents - adverse effects | Histamine H2 Antagonists - adverse effects | Omeprazole - adverse effects | Omeprazole - pharmacokinetics | HIV Protease Inhibitors - administration & dosage | Histamine H2 Antagonists - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | Ritonavir - pharmacokinetics | Pyrimidinones - blood | Anti-HIV Agents - pharmacokinetics | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Ranitidine - administration & dosage | Antiviral agents | Dosage and administration | Research | Drug interactions | Index Medicus
Journal Article
International Journal of Clinical Pharmacology and Therapeutics, ISSN 0946-1965, 2017, Volume 55, Issue 10, pp. 798 - 806
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 9/2014, Volume 31, Issue 9, pp. 2404 - 2419
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 11/2017, Volume 6, Issue 6, pp. 614 - 626
Palbociclib free base capsule is a weak base drug with highly pH‐dependent solubility. In vitro and in vivo studies evaluated the impact of acid‐reducing... 
free base capsule | pH‐dependent solubility | histamine‐2 receptor antagonist | acid‐reducing agent | local antacid | pharmacokinetics | fed condition | palbociclib | proton pump inhibitor | fast condition | pH-dependent solubility | acid-reducing agent | histamine-2 receptor antagonist | RABEPRAZOLE | INTRAGASTRIC ACIDITY | ANTICANCER AGENTS | KINASE 4/6 | MIXED MICELLES | BIOAVAILABILITY | SELECTIVE INHIBITOR | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | GASTRIC PH | DRUG-DRUG INTERACTIONS | Piperazines - administration & dosage | Proton Pump Inhibitors - pharmacology | Area Under Curve | Histamine H2 Antagonists - pharmacology | Pyridines - chemistry | Humans | Middle Aged | Bile Acids and Salts - chemistry | Pyridines - pharmacokinetics | Male | Piperazines - chemistry | Young Adult | Histamine H2 Antagonists - administration & dosage | Protein Kinase Inhibitors - chemistry | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Famotidine - administration & dosage | Micelles | Adult | Female | Piperazines - pharmacokinetics | Antacids - pharmacology | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Food-Drug Interactions | Solubility | Protein Kinase Inhibitors - administration & dosage | Rabeprazole - pharmacology | Famotidine - pharmacology | Antacids - administration & dosage | Hydrogen-Ion Concentration | Rabeprazole - administration & dosage
Journal Article
IET Nanobiotechnology, ISSN 1751-8741, 8/2016, Volume 10, Issue 4, pp. 190 - 194
There is no optimal imaging method for the detection of unknown infectious foci in some diseases. This study introduces a novel method in X-ray imaging of... 
Research Articles | Fourier transform infrared spectra | nanofabrication | human blood | murine model | sodium citrate | ultraviolet-visible spectroscopy | X-ray imaging | visible spectra | gold | tetrachloroauric acid reduction | nanoparticles | gentamicin-gold nanoparticle conjugate | polymers | Staphylococcus aureus | polyethylene glycol | ANTIBIOTICS | BACTERIA | disease | drugs | BIOCHEMICAL RESEARCH METHODS | nanomedicine | diseases | NANOSCIENCE & NANOTECHNOLOGY | diagnostic radiography | nanodrug | contrast agent | ENHANCED PERMEABILITY | ultraviolet spectra | VANCOMYCIN | microorganisms | X-ray images | Fourier transform infrared spectroscopy | Staphylococcal infection | SPECTRA | Gentamicins - chemistry | Gold - chemistry | Reproducibility of Results | Nanoconjugates - ultrastructure | Metal Nanoparticles - chemistry | Mice, Inbred C57BL | Radiographic Image Enhancement - methods | Contrast Media - pharmacokinetics | Tomography, X-Ray Computed - methods | Gentamicins - pharmacokinetics | Staphylococcal Infections - diagnostic imaging | Contrast Media - chemical synthesis | Animals | Anti-Bacterial Agents - chemistry | Sensitivity and Specificity | Anti-Bacterial Agents - pharmacokinetics | Mice | Mice, Inbred BALB C | Nanoconjugates - chemistry | Metal Nanoparticles - ultrastructure | Staphylococcal Infections - metabolism | Index Medicus | Conjugates | Contrast agents | Imaging | Citrates | X-rays | Nanostructure | Blood
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 10/2008, Volume 66, Issue 4, pp. 508 - 516
Journal Article